Marco gives clinicians instant access to the latest scientific evidence on Bladder Cancer, including FGFR2/3 alterations, PD-L1, NMIBC/MIBC staging, EAU/NCCN/ESMO guidelines and key trial data. The AI agent processes thousands of papers and guidelines to deliver precise, referenced answers in seconds.
Some answers to questions we often receive
Marco continuously integrates EAU/NCCN/ESMO guidelines for Bladder Cancer, covering recommendations by molecular subtype, disease stage and specific clinical scenarios including metastatic disease, perioperative settings and surveillance protocols.
Marco includes results from pivotal trials such as EV-301, JAVELIN Bladder 100, NORSE, with synthesis of their clinical practice implications and current recommendation levels across major international guidelines.
Marco synthesizes current evidence and guideline recommendations for Bladder Cancer in a format ready for tumor board discussion, covering diagnostic workup, therapeutic options by molecular profile and treatment sequencing, reducing preparation time significantly.
Yes. Marco processes evidence on key biomarkers in Bladder Cancer including FGFR2/3 alterations, PD-L1, NMIBC/MIBC staging, delivering updated therapeutic implications based on the latest available evidence, guideline recommendations and regulatory approvals.
Marco is designed for clinical evidence queries without processing patient-identifiable data. Queries address general scientific evidence, ensuring privacy compliance and regulatory adherence. The system operates in the physician's workflow without handling individual patient records.
Yes. Marco is designed to democratize access to high-quality clinical evidence for Bladder Cancer. Available via WhatsApp, it requires no special infrastructure, giving clinicians in any setting the same evidence quality as major academic centers.
Managing NMIBC with BCG and navigating new advanced bladder therapies requires constant updates that consume critical clinical time.